Fig. 3From: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesMatched targeted therapy for LM informed by CSF cfDNA. A Response and survival outcome of matched targeted therapy. B Time to LM progression from start of matched targeted therapy until LM progression for patients with intracranial benefit (partial response and stable disease). C Overall survival of matched targeted therapy; RANO-LM, Response Assessment in Neuro-Oncology-leptomeningeal metastases; RECIST, Response Evaluation Criteria in Solid Tumors; NA, not available; CSF, cerebrospinal fluidBack to article page